BridgeBio director granted RSUs and options

BridgeBio Pharma director Eric Aguiar received new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma director Eric Aguiar received new equity awards. On June 22, 2026, he was granted 3,990 restricted stock units, each representing one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.

The RSUs and the shares underlying the stock options vest in full on June 22, 2027, as long as he continues serving on the board through that date. After these awards, he holds 10,579 shares of common stock directly, plus the 5,277 options expiring on June 21, 2036.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 2 txns

Insider AGUIAR ERIC

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 10,579 shares (Direct)

Footnotes (3)

F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSUs granted: 3,990 units Stock options granted: 5,277 options Option exercise price: $68.92/share +3 more

6 metrics

RSUs granted 3,990 units Restricted stock units granted on June 22, 2026

Stock options granted 5,277 options Director stock option award on June 22, 2026

Option exercise price $68.92/share Conversion or exercise price for granted options

Common shares after award 10,579 shares Total common stock held directly after transactions

Option expiration June 21, 2036 Expiration date of 5,277 stock options

Vesting date June 22, 2027 Full vesting for RSUs and option-underlying shares

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 68.9200."

exercise price financial

"conversion_or_exercise_price: "68.9200" for the stock option grant."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The RSUs vest in full on June 22, 2027, subject to continued service."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Pharma (BBIO) report for Eric Aguiar?

BridgeBio Pharma reported that director Eric Aguiar received equity awards on June 22, 2026. He was granted 3,990 restricted stock units and 5,277 stock options as part of his compensation, rather than buying or selling shares on the open market.

How many BridgeBio Pharma (BBIO) RSUs were granted to Eric Aguiar?

Eric Aguiar received 3,990 restricted stock units from BridgeBio Pharma. Each RSU represents a contingent right to receive one share of common stock, subject to vesting conditions tied to his continued service on the company’s board of directors through June 22, 2027.

What are the terms of Eric Aguiar’s BridgeBio Pharma (BBIO) stock options?

Aguiar was granted 5,277 stock options with a $68.92 exercise price. These options give him the right to buy BridgeBio common shares at that price, vesting in full on June 22, 2027, and expiring on June 21, 2036 if not exercised earlier.

When do Eric Aguiar’s BridgeBio (BBIO) RSUs and options vest?

Both the 3,990 restricted stock units and the 5,277 option-underlying shares vest in full on June 22, 2027. Vesting requires Aguiar to continue serving on BridgeBio Pharma’s board of directors through that vesting date, according to the award terms.

How many BridgeBio Pharma (BBIO) shares does Eric Aguiar hold after this Form 4?

Following the reported awards, Aguiar directly holds 10,579 shares of BridgeBio Pharma common stock. In addition, he holds 5,277 stock options that are currently unexercised, providing potential future ownership if he chooses to exercise them after vesting.

Under which plan were Eric Aguiar’s BridgeBio (BBIO) RSUs granted?

The restricted stock units were granted under BridgeBio Pharma’s 2021 Amended and Restated Stock Option and Incentive Plan. This plan governs equity-based compensation, including RSUs and stock options, for directors and other eligible participants at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/24/2026 - 06:06 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGUIAR ERIC

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		A⁽¹⁾		3,990	A	$0⁽²⁾	10,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		⁽³⁾	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR